![Valerie Odegard](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Valerie Odegard
Directeur/Bestuurslid bij
ODYSSEY THERAPEUTICS, INC.
Vermogen: - $ op 30-09-2026
Profiel
Dr. Valerie Odegard is a Chief Executive Officer at Dovetail Therapeutics, Inc., a Venture Partner at OrbiMed Advisors Private Equity and an Independent Director at Odyssey Therapeutics, Inc. She is on the Board of Directors at Odyssey Therapeutics, Inc. and Abata Therapeutics, Inc. Dr. Odegard was previously employed as a President & Chief Scientific Officer by Silverback Therapeutics, Inc. and a Vice President-Research by Juno Therapeutics, Inc. She received her undergraduate degree from Wake Forest University and a doctorate degree from Yale University.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 08-05-2026 | 0 ( -.--% ) | - $ | 30-09-2026 |
Actieve functies van Valerie Odegard
| Bedrijven | Functie | Begin |
|---|---|---|
| ODYSSEY THERAPEUTICS, INC. | Directeur/Bestuurslid | 01-10-2021 |
Abata Therapeutics, Inc.
 Abata Therapeutics, Inc. BiotechnologyHealth Technology Engages in development of treg cell therapies for serious autoimmune and inflammatory diseases | Directeur/Bestuurslid | 29-07-2021 |
OrbiMed Advisors Private Equity
 OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity invests in companies located across the globe primarily in North America, Asia, Europe and Israel. The firm focuses on biopharmaceuticals, medical technology and healthcare services. It participates in seed-stage, early stage, growth transactions. It also provides debt capital and monetize royalty streams and invests in publicly-traded companies. | Private Equity Investor | 01-10-2022 |
Eerdere bekende functies van Valerie Odegard
| Bedrijven | Functie | Einde |
|---|---|---|
| ARS PHARMACEUTICALS, INC. | President | 02-09-2022 |
| JUNO THERAPEUTICS INC | Hoofd Techniek/Wetenschap/O&O | 01-10-2016 |
Opleiding van Valerie Odegard
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
64
Eerstegraads connecties
7
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 7 |
|---|---|
Wake Forest University
 Wake Forest University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Yale University
 Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
OrbiMed Advisors Private Equity
OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity invests in companies located across the globe primarily in North America, Asia, Europe and Israel. The firm focuses on biopharmaceuticals, medical technology and healthcare services. It participates in seed-stage, early stage, growth transactions. It also provides debt capital and monetize royalty streams and invests in publicly-traded companies. | Finance |
Juno Therapeutics, Inc.
 Juno Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company to treat cancer, HIV and cardiovascular diseases | Health Technology |
Silverback Therapeutics, Inc.
 Silverback Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company | Health Technology |
Odyssey Therapeutics, Inc.
 Odyssey Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops therapeutics for autoimmune and inflammatory diseases | Health Technology |
Abata Therapeutics, Inc.
Abata Therapeutics, Inc. BiotechnologyHealth Technology Engages in development of treg cell therapies for serious autoimmune and inflammatory diseases | Health Technology |
